The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month ...

Luca Maini, assistant professor of health care policy in the Blavatnik Institute at Harvard Medical School, studies ...

Ascletis Pharma announced new preclinical and Phase Ib clinical results for its portfolio of next-generation obesity drug candidates, including ASC36, ASC35, and ASC30, developed using its proprietary ...

A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more ...

The White House announced reduced pricing for the popular weight-loss drugs made by Eli Lilly and Novo Nordisk.

Several pharmaceutical companies have said they will sell drugs directly to patients in the US and offer discounts ...

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce ...

President Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their ...

Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to lower prices of their ...

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...

An announcement from LB Pharmaceuticals, Inc. ( ($LBRX) ) is now available. On November 12, 2025, LB Pharmaceuticals announced the appointment of ...